A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

NCT07310420 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Breast Cancer

Interventions

DRUG: ZOLADEX

Sponsor

TerSera Therapeutics LLC